Genmab, a Danish biotech company, is relocating its U.S. headquarters from Carnegie Center to 777 Scudders Mill Road, taking over 90,000 square feet formerly occupied by Bristol-Myers Squibb. Genmab specializes in the creation and development of differentiated antibody therapeutics for the treatment of cancer. The Scudders Mill Road facility has been vacant since BMS moved to its new 650,000 square-foot headquarters on Princeton Pike in Lawrenceville.
A team from Colliers International led by Charlie Hatfield and Brett Incollingo represented the property owner, Trawler Capital Management, in the deal along with Tom Romano of JLL. Genmab was represented by JLL’s Dan Spero, Craig Eisenhardt, and Jason Benson.
The 125-acre campus was built for Bristol-Myers Squibb and designed by the Hillier Group. The property consists of three, five-story, 220,000-square-foot office buildings.
“The combination of working with a well-funded and transaction oriented owner, who controls the best quality product in the market, and is tenant and broker friendly is always a winning combination in the very competitive world of attracting and retaining world class tenants like Genmab,” Hatfield said.
The office space will include all new conference and meeting facilities, private and reservable wellness rooms, bike and pedestrian paths, outdoor amphitheater and terrace, a media lab, electric car chargers, and a full-service cafeteria.
“We are pleased to be part of the 777 Scudders Mill Road campus environment, which supports our ambitions to nurture Genmab’s corporate culture in a new and vibrant workplace environment that aligns with our company vision,” said Chris Cozic, Genmab’s corporate vice president of human resources. “New Jersey’s ever-dynamic and innovative life-sciences ecosystem, along with the high-skilled labor market in the state, made the campus an ideal location to continue our growth trajectory.”
Genmab Inc. (GEN), 902 Carnegie Center, Suite 301, Princeton 08540. 609-430-2481. Lisa Drakeman PhD, CEO. www.genmab.com.
A new tenant is also coming to Bristol-Myers Squibb’s Hopewell campus, a million-square-foot facility the pharmaceutical hopes to turn into a multi-tenant research and development center. PTC Therapeutics announced it had signed a lease for 185,000 square feet of space.
The South Plainfield-based pharmaceutical company develops oral medications to regulate gene expression. The company will maintain its current headquarters but plans to move its research operations to the Hopewell site in 2020.
